[
  {
    "ts": null,
    "headline": "Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound",
    "summary": "Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...",
    "url": "https://finnhub.io/api/news?id=0050d3be437bea5b1beea859c951bdec0eb66a9324100d4466d967679442edaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766016992,
      "headline": "Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound",
      "id": 137817889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year returns. See our latest analysis for Biogen. That 19.6% 3 month share price return stands out against a still modest 14.7% year to date share price gain and a disappointing 3 year total shareholder return of around negative 40%. This suggests sentiment has only recently started to warm up again. If...",
      "url": "https://finnhub.io/api/news?id=0050d3be437bea5b1beea859c951bdec0eb66a9324100d4466d967679442edaf"
    }
  }
]